EULAR 2026 Titles for Covered Companies

Research evidence excerpt

EULAR 2026 Titles for Covered Companies

is

Months in Late-Onset Rheumatoid Arthritis

Saturday, June 6 10:15 Long-Term Risk of Malignancies with Upadacitinib in Comparison to Adalimumab in POS1231 Poster View Jerome Avouac (Paris, France) Rheumatoid Arthritis

Rheumatoid Arthritis Up to 5 Years: Post Hoc Analysis of Six Clinical Trials

Saturday, June 6 10:15 Consistent long-term safety of filgotinib in rheumatoid arthritis over a median of 4.8 POS1238 Poster View Rene Westhovens (Maaseik, Belgium) Rheumatoid Arthritis

years: Integrated evidence from seven clinical trials

Saturday, June 6 10:15 ANTIFIBROTICS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE: POS1247 Poster View Ana Serrano-Combarro (Spain) Rheumatoid Arthritis

COMPARATIVE STUDY OF NINTEDANIB VS PIRFENIDONE. NATIONAL

MULTICENTER STUDY OF 107 PATIENTS

Saturday, June 6 10:15 Safety of early tapering of biologic therapy in rheumatoid arthitis: a comparative study POS1248 Poster View Paola Jauregui Rojas (Trujillo, Peru) Rheumatoid Arthritis

at 12 and 24 months

Saturday, June 6 10:15 Effectiveness of swapping vs. cycling in remission achievement in patients with POS1252 Poster View Eduardo Dourado (Portugal) Rheumatoid Arthritis

rheumatoid arthritis after failing a first TNFi due to inefficacy: real-world study (RA-

Mission)

Saturday, June 6 10:15 Subcutaneous versus intravenous ultra-low dose rituximab in patients with POS1266 Poster View Pauline Bovens (Nijmegen, Rheumatoid Arthritis

rheumatoid arthritis: a randomised controlled non-inferiority trial Netherlands)

Saturday, June 6 10:15 Real-World Radiographic Outcomes of Sarilumab in Rheumatoid Arthritis: A POS1286 Poster View Masahiro Tada (Osaka, Japan) Rheumatoid Arthritis

Multicenter Study of Structural Remission and Progression